Tapentadol: an effective option for the treatment of back pain
Open Access
- 1 May 2019
- journal article
- review article
- Published by Taylor & Francis Ltd in Journal of Pain Research
- Vol. ume 12, 1521-1528
- https://doi.org/10.2147/jpr.s190176
Abstract
Back pain, including low back pain and neck pain, is the leading cause of disability worldwide. This type of pain is challenging to treat, since it presents both a nociceptive and a neuropathic component. The latter also contributes to the evolution of pain toward chronification. Treatment selection should therefore consider the ability to prevent this event. Tapentadol is characterized by a unique and innovative peculiar mechanism of action that makes it the first representative of a new class of central strong analgesics referred to as MOR-NRI. This molecule acts both on the nociceptive and neuropathic components of pain, and it can therefore be effective in the treatment of a mixed pain condition such as back pain. This narrative review discusses the rationale for the use of tapentadol in both low back pain and neck pain and presents available clinical data. Overall, data show that tapentadol prolonged release is a well-grounded treatment for chronic back pain, sustained by a strong mechanistic rationale and robust evidence. Given also the availability of long-term efficacy and safety data, we believe that this molecule should be considered as an elective therapy for chronic back pain.Keywords
This publication has 40 references indexed in Scilit:
- Tapentadol Prolonged Release for Severe Chronic Pain: Results of a Noninterventional Study Involving General Practitioners and InternistsJournal of Pain & Palliative Care Pharmacotherapy, 2013
- Clinical course of non‐specific low back pain: A systematic review of prospective cohort studies set in primary careEuropean journal of pain, 2012
- Tapentadol increases levels of noradrenaline in the rat spinal cord as measured by in vivo microdialysisNeuroscience Letters, 2012
- The burden of chronic low back pain with and without a neuropathic component: a healthcare resource use and cost analysisJournal of Medical Economics, 2011
- The epidemiology of neck painBest Practice & Research Clinical Rheumatology, 2010
- Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally‐acting analgesics on the horizon?European Journal of Pain Supplements, 2010
- An updated overview of clinical guidelines for the management of non-specific low back pain in primary careEuropean Spine Journal, 2010
- Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III studyExpert Opinion on Pharmacotherapy, 2010
- EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revisionEuropean Journal of Neurology, 2010
- The Burden and Determinants of Neck Pain in the General PopulationSpine, 2008